BioVex site map
Home page
About Biovex
- The company, management, board and investors
OncoVex
- BioVex believes OncoVEXGM-CSF has the potential to become a leading standard of care in the treatment of many solid tumors based on the strength of clinical data so far generated coupled with the relatively benign side effect profile noted to date.
ImmunoVEX
- BioVex recently commenced clinical testing in the UK with this vaccine candidate for the prevention and potentially the treatment of genital herpes.
Press: BioVex press releases and news archive.
- 4 March 2010
BioVex initiates Phase 1 Clinical Trial with its genital herpes vaccine, ImmunoVEXHSV2 - 4 January, 2010
BioVex appoints Tim Hanke as VP Commercial Operations - November 10, 2009
BioVex completes $70 million financing to conclude pivotal study with its pioneering cancer treatment, OncoVEXGM-CSF - November 2, 2009
BioVex announces publication of Phase 2 Melanoma Results with OncoVEXGM-CSF
in The Journal of Clinical Oncology - September 15, 2009
BioVex agrees SPA with the FDA for a pivotal Phase III study with OncoVEXGM-CSF in head and neck cancer - May 15, 2009
BioVex to announce updated Survival Data from a Phase II clinical study of OncoVEXGM-CSF in Metastatic Melanoma at the 2009 American Society of Clinical Oncology meeting - May 15, 2009
BioVex to report Phase I/II Clinical Trial Results for the front line treatment of head and neck cancer with OncoVEXGM-CSF at the 2009 American Society of Clinical Oncology meeting - April 14, 2009
BioVex commences OncoVEXGM-CSF Phase 3 Trial in Metastatic Melanoma - March 30, 2009
BioVex raises $40 Million in first close of Series F Financing - August 20, 2008
BioVex announces regulatory clearance to commence a clinical study with ImmunoVEXHSV2; a vaccine candidate for genital herpes - June 1, 2008
BioVex reports positive Phase II clinical trial results of OncoVEXGM-CSF in metastatic melanoma at the 2008 American Society of Clinical Oncology Meeting - May 16, 2008
BioVex to report Phase II clinical trial results of OncoVEXGM-CSF in metastatic melanoma at the 2008 American Society of Clinical Oncology Meeting - April 22, 2008
BioVex agrees SPA with the FDA for a pivotal study with OncoVEXGM-CSF in metastatic melanoma and announces presentation of Phase II results at ASCO - January 2, 2008
BioVex to present at The JP Morgan 26th Annual Healthcare Conference - November 15, 2007
BioVex closes second round of Series E Financing
Second and Final Close Completes $35 Million Financing
Employment
- Current employment opportunities with BioVex in the US and UK
Contact Us
Legal Notice
